<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427440</url>
  </required_header>
  <id_info>
    <org_study_id>20050253</org_study_id>
    <nct_id>NCT00427440</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Treat Advanced Malignant Glioma</brief_title>
  <official_title>A Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the&#xD;
      treatment of Advanced Malignant Glioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess best objective confirmed response rate in subjects with advanced malignant glioma receiving AMG 102 treatment</measure>
    <time_frame>Week 9 from first dose of AMG 102</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety profile of AMG 102 in subjects with advanced malignant glioma</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate overall survival and progression-free survival rates in this population</measure>
    <time_frame>8 week intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the duration of response and time to response in this population</measure>
    <time_frame>Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetics of AMG 102 in subjects with advanced malignant glioma</measure>
    <time_frame>Weeks 1, 5, and 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Advanced Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>AMG 102 at 10 mg/kg Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 102 at 20 mg/kg Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102 at 20 mg/kg</intervention_name>
    <description>AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks</description>
    <arm_group_label>AMG 102 at 20 mg/kg Dose Level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102 at 10 mg/kg</intervention_name>
    <description>AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks</description>
    <arm_group_label>AMG 102 at 10 mg/kg Dose Level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects with documented histologically confirmed primary grade 4 advanced malignant&#xD;
             glioma&#xD;
&#xD;
          -  no more than 3 prior relapses or prior systemic treatments&#xD;
&#xD;
          -  recurrent disease documented by MRI after prior therapy&#xD;
&#xD;
          -  must have at least one site of bidimensionally measurable disease:&#xD;
&#xD;
          -  archived tissue from the initial diagnosis of advanced malignant glioma or upon&#xD;
             transformation to advanced malignant glioma are available for central review within&#xD;
             approximately 4 weeks after enrollment&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  Karnofsky performance score ≥ 60%&#xD;
&#xD;
          -  hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  absolute neutrophil count ≥ 1.5 x 10(9th)/L&#xD;
&#xD;
          -  platelet count ≥ 100 x 10(9th)/L&#xD;
&#xD;
          -  serum creatinine ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  alanine aminotransferase ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  serum total bilirubin ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  before any study-specific procedure, the appropriate written informed consent must be&#xD;
             obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of central nervous system bleeding as defined by stroke or intraocular bleed&#xD;
             (including embolic stroke) within 6 months before enrollment&#xD;
&#xD;
          -  evidence of acute intracranial/intratumoral hemorrhage; except for subjects with&#xD;
             stable grade 1 hemorrhage&#xD;
&#xD;
          -  received radiation therapy within 4 weeks before enrollment or have not recovered from&#xD;
             the toxic effects of such therapy&#xD;
&#xD;
          -  treated previously with any c-Met or HGF targeted therapy&#xD;
&#xD;
          -  treated with thalidomide or tamoxifen within 1 week before enrollment or has not&#xD;
             recovered from the toxic effects of such cancer therapy&#xD;
&#xD;
          -  treated with immunotherapeutic agents, vaccines or mAb therapy within 4 weeks before&#xD;
             enrollment or have not recovered from the toxic effects of such cancer therapy&#xD;
&#xD;
          -  treated with alkylating agents within 4 weeks before enrollment or has not recovered&#xD;
             from the toxic effects of such cancer therapy&#xD;
&#xD;
          -  treated with chemotherapy (non-alkylating agents) within 2 weeks before enrollment or&#xD;
             has not recovered from the toxic effects of such cancer therapy&#xD;
&#xD;
          -  surgical resection of brain tumor within 4 weeks before enrollment or have not&#xD;
             recovered from acute side effects of such therapy, except for neurological effects&#xD;
&#xD;
          -  plans to receive surgery, radiation therapy or other elective surgeries during the&#xD;
             course of the study&#xD;
&#xD;
          -  concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,&#xD;
             congestive cardiac failure, myocardial infarction within 6 months before enrollment)&#xD;
             that could compromise participation in the study&#xD;
&#xD;
          -  active infection within 7 days before enrollment&#xD;
&#xD;
          -  past or current history of another neoplasm, except for curatively treated&#xD;
             non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid&#xD;
             cancer with no known active disease present and no curative or adjuvant treatment&#xD;
             administered for the last 3 years&#xD;
&#xD;
          -  documented history of human immunodeficiency virus&#xD;
&#xD;
          -  documented history of chronic viral hepatitis&#xD;
&#xD;
          -  concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except:&#xD;
&#xD;
               -  Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium [Lovenox] and&#xD;
                  unfractionated heparin for prophylaxis against central venous catheter thrombosis&#xD;
                  is allowed&#xD;
&#xD;
               -  Use of low dose warfarin (&lt; 2 mg/day) for prophylaxis against central venous&#xD;
                  catheter thrombosis is allowed&#xD;
&#xD;
          -  currently enrolled in or has not yet completed at least 30 days since ending other&#xD;
             investigational device or therapeutic study(s)&#xD;
&#xD;
          -  had major surgery within 4 weeks before enrollment or recovering from prior surgery&#xD;
&#xD;
          -  known allergy or sensitivity to any of the excipients in the investigational product&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
&#xD;
          -  unwilling to use adequate contraceptive precautions during the course of the study and&#xD;
             for 6 months after the last administration of investigational product, for:&#xD;
&#xD;
               -  male subjects&#xD;
&#xD;
               -  female subjects who are not post-menopausal (no menstrual period for a minimum of&#xD;
                  12 months at study entry) or documented surgically sterile will not be bound to&#xD;
                  this exclusion&#xD;
&#xD;
          -  previously treated with AMG 102&#xD;
&#xD;
          -  previously enrolled into this study&#xD;
&#xD;
          -  will not be available for follow-up assessment&#xD;
&#xD;
          -  has other disorders that compromises the ability of the subject to give written&#xD;
             informed consent and/or comply with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr;13(4):437-46. doi: 10.1093/neuonc/noq198. Epub 2011 Feb 4.</citation>
    <PMID>21297127</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <disposition_first_submitted>April 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 27, 2015</disposition_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Brain Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rilotumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

